The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Rituximab Combined With Chemotherapy in Burkitt's Lymphoma
Official Title: Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)
Study ID: NCT00388193
Brief Summary: The purpose of this clinical trial is to prove the efficacy of the following new regimen treatment: * Administration of anti-CD20 (Rituximab) combined with chemotherapy. * Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics (block C) * Prophylactic administration of G-CSF after all chemotherapy cycles * local irradiation after 6 cycle if CNS was affected or if there are residual tumour
Detailed Description: Clinical Trial with a pharmaceutical speciality in new conditions to use.
Minimum Age: 15 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hospital General de Alicante, Alicante, , Spain
Hospital "Santa Creu i Sant Pau", Barcelona, , Spain
Hospital Clínico y Provincial de Barcelona, Barcelona, , Spain
Complejo Hospitalario de Cáceres, Cáceres, , Spain
Hospital general de Jerez de la Frontera, Jerez de la Frontera, , Spain
Hospital Juan Canalejo, La Coruña, , Spain
Hospital Clínico San Carlos de Madrid, Madrid, , Spain
Hospital Doce de Octubre, Madrid, , Spain
Hospital Universitario Morales Meseguer, Murcia, Murcia, , Spain
Hospital Carlos Haya, Málaga, , Spain
Hospital Son Dureta, Palma de Mallorca, , Spain
Hospital Clínico Universitario de Salamanca, Salamanca, , Spain
Hospital Universitario Virgen del Rocío, Sevilla, , Spain
Hospital La Fe, Valencia, , Spain
Hospital Txagorritxu, Vitoria, , Spain
Name: Ribera Josep Mª, Dr
Affiliation: Germans Trias i Pujol Hospital
Role: STUDY_CHAIR